Novartis CEO cites political influence in FDA drug review

09/28/2007 | Financial Times (tiered subscription model)

Political pressure to address drug safety controversies has made the FDA overcautious in reviewing new drugs for approval, Novartis AG CEO Daniel Vasella said in a conference on Friday. Two drugs in Novartis' pipeline, the diabetes drug Galvus and the painkiller Prexige, recently have met significant regulatory delays with the FDA.

View Full Article in:

Financial Times (tiered subscription model)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park
Assistant General Counsel/Senior Corporate Counsel
South San Francisco, CA
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Fort Worth, TX
Director, Senior Legal Counsel
Fort Worth, TX